Multi-domain interventions for the prevention of dementia and cognitive decline
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dementia is a worldwide concern. Its global prevalence is increasing. Currently, no effective medical treatment exists to cure or to delay the onset of cognitive decline or dementia. Up to 40% of dementia is attributable to potentially modifiable risk factors, which has led to the notion that targeting these risk factors might reduce the incidence of cognitive decline and dementia. Since sporadic dementia is a multifactorial condition, thought to derive from multiple causes and risk factors, multi-domain interventions may be more effective for the prevention of dementia than those targeting single risk factors. OBJECTIVES: To assess the effects of multi-domain interventions for the prevention of cognitive decline and dementia in older adults, including both unselected populations and populations at increased risk of cognitive decline and dementia. SEARCH METHODS: We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group's register, MEDLINE (Ovid SP), Embase (Ovid SP), PsycINFO (Ovid SP), CINAHL (EBSCOhost), Web of Science Core Collection (ISI Web of Science), LILACS (BIREME), and ClinicalTrials.gov on 28 April 2021. We also reviewed citations of reference lists of included studies, landmark papers, and review papers to identify additional studies and assessed their suitability for inclusion in the review. SELECTION CRITERIA: We defined a multi-domain intervention as an intervention with more than one component, pharmacological or non-pharmacological, but not consisting only of two or more drugs with the same therapeutic target. We included randomised controlled trials (RCTs) evaluating the effect of such an intervention on cognitive functioning and/or incident dementia. We accepted as control conditions any sham intervention or usual care, but not single-domain interventions intended to reduce dementia risk. We required studies to have a minimum of 400 participants and an intervention and follow-up duration of at least 12 months. DATA COLLECTION AND ANALYSIS: We initially screened search results using a 'crowdsourcing' method in which members of Cochrane's citizen science platform identify RCTs. We screened the identified citations against inclusion criteria by two review authors working independently. At least two review authors also independently extracted data, assessed the risk of bias and applied the GRADE approach to assess the certainty of evidence. We defined high-certainty reviews as trials with a low risk of bias across all domains other than blinding of participants and personnel involved in administering the intervention (because lifestyle interventions are difficult to blind). Critical outcomes were incident dementia, incident mild cognitive impairment (MCI), cognitive decline measured with any validated measure, and mortality. Important outcomes included adverse events (e.g. cardiovascular events), quality of life, and activities of daily living (ADL). Where appropriate, we synthesised data in random-effects meta-analyses. We expressed treatment effects as risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs). MAIN RESULTS: We included nine RCTs (18.452 participants) in this review. Two studies reported incident dementia as an outcome; all nine studies reported a measure for cognitive functioning. Assessment of cognitive functioning was very heterogeneous across studies, ranging from complete neuropsychological assessments to short screening tests such as the mini-mental state examination (MMSE). The duration of the interventions varied from 12 months to 10 years. We compared multi-domain interventions against usual care or a sham intervention. Positive MDs and RRs <1 favour multi-domain interventions over control interventions. For incident dementia, there was no evidence of a difference between the multi-domain intervention group and the control group (RR 0.94, 95% CI 0.76 to 1.18; 2 studies; 7256 participants; high-certainty evidence). There was a small difference in composite Z-score for cognitive function measured with a neuropsychological test battery (NTB) (MD 0.03, 95% CI 0.01 to 0.06; 3 studies; 4617 participants; high-certainty evidence) and with the Montreal Cognitive Assessment (MoCA) scale (MD 0.76 point, 95% CI 0.05 to 1.46; 2 studies; 1554 participants), but the certainty of evidence for the MoCA was very low (due to serious risk of bias, inconsistency and indirectness) and there was no evidence of an effect on the MMSE (MD 0.02 point, 95% CI -0.06 to 0.09; 6 studies; 8697participants; moderate-certainty evidence). There was no evidence of an effect on mortality (RR 0.93, 95% CI 0.84 to 1.04; 4 studies; 11,487 participants; high-certainty evidence). There was high-certainty evidence for an interaction of the multi-domain intervention with ApoE4 status on the outcome of cognitive function measured with an NTB (carriers MD 0.14, 95% CI 0.04 to 0.25, noncarriers MD 0.04, 95% CI -0.02 to 0.10, P for interaction 0.09). There was n
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
RetractedGRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Sick individuals and sick populations
Rose, G. (2001) · International Journal of Epidemiology · doi:10.1093/ije/30.3.427 · Cited by 3,736
Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60461-5 · Cited by 3,689
Cognitive reserve in ageing and Alzheimer's disease
Stern, Y. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70191-6 · Cited by 3,557
Explaining the decrease in U.S. deaths from coronary disease, 1980–2000
Ford, E. S., Ajani, U. A., Croft, J. B., Critchley, J. A., Labarthe, D. R., Kottke, T. E., Giles, W. H., & Capewell, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa053935 · Cited by 2,757
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
15-year longitudinal study of blood pressure and dementia
Skoog, I., Nilsson, L., Persson, G., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L.-A., Odén, A., & Svanborg, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90608-x · Cited by 1,726
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618
Research works printed but not linked: 23
- Alexopoulos, 2003, Vascular disease, depression, and dementia, Journal of the American Geriatrics Society, 51, 1178, 10.1046/j.1532-5415.2003.51373.x · DOI · Paper page
- Areosa Sastre, 2017, Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD003804.pub2 · DOI · Paper page
- Barnes, 2011, The projected effect of risk factor reduction on Alzheimer's disease prevalence, Lancet Neurology, 10, 819, 10.1016/S1474-4422(11)70072-2 · DOI · Paper page
- Brown, 2013, Multiple effects of physical activity on molecular and cognitive signs of brain aging: can exercise slow neurodegeneration and delay Alzheimer's disease?, Molecular Psychiatry, 18, 864, 10.1038/mp.2012.162 · DOI · Paper page
- Coley, 2008, Dementia prevention: methodological explanations for inconsistent results, Epidemiologic Reviews, 30, 35, 10.1093/epirev/mxn010 · DOI · Paper page
- Higgins JPT Thomas J Chandler J Cumpston M Li T Page MJ Welch VA (editors) Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019) Cochrane, 2019. Available from www.training.cochrane.org/handbook.The Cochrane Collaboration, 2011. Available from handbook.cochrane.org · DOI · Paper page
- Kessing, 2004, Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder?, Journal of Neurology, Neurosurgery, and Psychiatry, 75, 1662, 10.1136/jnnp.2003.031773 · DOI · Paper page
- Leckie, 2014, BDNF mediates improvements in executive function following a 1-year exercise intervention, Frontiers in Human Neuroscience, 8, 985, 10.3389/fnhum.2014.00985 · DOI · Paper page
- Luchsinger, 2009, Adiposity, type 2 diabetes, and Alzheimer's disease, Journal of Alzheimer's Disease, 16, 693, 10.3233/JAD-2009-1022 · DOI · Paper page
- McCarrey, 2015, Postmenopausal hormone therapy and cognition, Hormones and Behaviour, 74, 167, 10.1016/j.yhbeh.2015.04.018 · DOI · Paper page
- Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Medicine, 6, e1000097, 10.1371/journal.pmed.1000097 · DOI · Paper page
- Norton, 2014, Potential for primary prevention of Alzheimer's disease: an analysis of population-based data, Lancet Neurology, 13, 788, 10.1016/S1474-4422(14)70136-X · DOI · Paper page
- Ott, 1999, Diabetes mellitus and the risk of dementia: the Rotterdam Study, Neurology, 53, 1937, 10.1212/WNL.53.9.1937 · DOI · Paper page
- Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014
- Richard, 2009, Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress, Alzheimer Disease and Associated Disorders, 23, 198, 10.1097/WAD.0b013e31819783a4 · DOI · Paper page
- Solomon, 2007, Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study, Neurology, 68, 751, 10.1212/01.wnl.0000256368.57375.b7 · DOI · Paper page
- Solomon, 2014, Advances in the prevention of Alzheimer's disease and dementia, Journal of Internal Medicine, 275, 229, 10.1111/joim.12178 · DOI · Paper page
- Tolppanen, 2014, Midlife and late-life body mass index and late-life dementia: results from a prospective population-based cohort, Journal of Alzheimer's Disease, 38, 201, 10.3233/JAD-130698 · DOI · Paper page
- Tzourio, 2014, Is hypertension associated with an accelerated aging of the brain?, Hypertension, 63, 894, 10.1161/HYPERTENSIONAHA.113.00147 · DOI
- Middelaar, 2018, Blood pressure-lowering interventions to prevent dementia: a systematic review and meta-analysis, Journal of Hypertension, 36, 1780, 10.1097/HJH.0000000000001829 · DOI · Paper page
- Vliet, 2009, The influence of age on the association between cholesterol and cognitive function, Experimental Gerontology, 44, 112, 10.1016/j.exger.2008.05.004 · DOI
- Winblad, 2016, Defeating Alzheimer's disease and other dementias: a priority for European science and society, Lancet Neurology, 15, 455, 10.1016/S1474-4422(16)00062-4 · DOI · Paper page
- Yehuda, 2002, The role of polyunsaturated fatty acids in restoring the aging neuronal membrane, Neurobiology of Aging, 23, 843, 10.1016/S0197-4580(02)00074-X · DOI · Paper page
Cited by
Izquierdo, M., de Souto Barreto, P., Arai, H., Bischoff-Ferrari, H. A., Cadore, E. L., Cesari, M., Chen, L.-K., Coen, P. M., Courneya, K. S., Duque, G., et al. (2025) · The Journal of nutrition, health and aging · doi:10.1016/j.jnha.2024.100401 · Cited by 273
Social participation and risk of developing dementia
Sommerlad, A., Kivimäki, M., Larson, E. B., Röhr, S., Shirai, K., Singh-Manoux, A., & Livingston, G. (2023) · Nature Aging · doi:10.1038/s43587-023-00387-0 · Cited by 207
Multi-domain interventions for the prevention of dementia and cognitive decline
Hafdi, M., Hoevenaar-Blom, M. P., & Richard, E. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013572.pub2 · Cited by 124
Self-citationZülke, A. E., Pabst, A., Luppa, M., Roehr, S., Seidling, H., Oey, A., Cardona, M. I., Blotenberg, I., Bauer, A., Weise, S., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13486 · Cited by 90
Coley, N., Giulioli, C., Aisen, P. S., Vellas, B., & Andrieu, S. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101777 · Cited by 62
Metadata
- Authors
- Hafdi, M., Hoevenaar-Blom, M. P., & Richard, E.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2020-04-02
- Volume
- 11
- Pages
- CD013572-CD013572
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W3014841452
- Cited by
- 65
- References
- 52
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Update notices
- new_version (2021-11-08)
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multi-domain interventions for the prevention of dementia and cognitive decline. https://app.cochat.ai/papers/10.1002/14651858.cd013572
- The paper
- Hafdi, M., Hoevenaar-Blom, M. P., & Richard, E. (2020). Multi-domain interventions for the prevention of dementia and cognitive decline. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd013572
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.